Zobrazeno 1 - 10
of 174
pro vyhledávání: '"B. Drewelow"'
Publikováno v:
Der Internist. 44:1444-1449
During the last few years 3 important drugs (terfenadine, mibefradil, cisapride) had to been withdrawn from the market because of serious drug-drug interactions. Polypragmacy, not only in advanced age, is often applied. Consequently the possibility o
Publikováno v:
Clinical Therapeutics. 39:e29
Autor:
B, Drewelow, J, Majcher-Peszynska
Publikováno v:
Drug research. 64
Autor:
S Pietzyk, A Wollny, K Ertzinger, S Bernard, U Jähde, F Böhmer, M Redaelli, M Kulick, P Thürmann, S Wilm, B Drewelow, A Altiner, S Nehls
Publikováno v:
Zeitschrift für Palliativmedizin. 15
Autor:
J, Majcher-Peszynska, M, Loebermann, S, Klammt, S, Frimmel, R G, Mundkowski, T, Welte, E C, Reisinger, B, Drewelow, G, Rainer
Publikováno v:
Infection
PURPOSE Age related physiological changes affect body systems altering pharmacokinetics which may potentiate or alter the effects of drugs. The aim of this study was to assess the influence of age on the steady state pharmacokinetics and pharmacokine
Publikováno v:
DMW - Deutsche Medizinische Wochenschrift. 137
Publikováno v:
Klinische Monatsblatter fur Augenheilkunde. 229(2)
The suitability of a high-hydrophilic osmotic self-inflating hydrogel expander consisting of a co-polymer of N-vinylpyrolidone and methyl methacrylate as a drug delivery system for antibiotics to prevent a postoperative infection was investigated in
Autor:
J. Meinshausen, Ulrich Klotz, K. Bühl, A. Harings-Kaim, G. Engel, B. Drewelow, Ehab S. El Desoky
Publikováno v:
Therapeutic Drug Monitoring. 15:281-288
In three groups (each n = 12) of unselected hospitalized patients treated either with digoxin, theophylline, or gentamicin routinely performed TDM measurement of trough steady-state plasma levels (+ peak levels in case of gentamicin) was combined wit
Autor:
J. Majcher-Peszynska, B. Drewelow
Publikováno v:
Drug Research. 64:S6-S7
Publikováno v:
The International journal of artificial organs. 30(10)
Information about the elimination and the adequate dosing of levofloxacin during renal replacement therapy is scarce. The aim of this study was to characterize in vitro the elimination of levofloxacin during continuous venovenous hemodialysis (CVVHD)